Pharmacopeia and BMS Enter into an Alliance that Supports the Growth of Both Companies
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 71 (Table of Contents)
Published: 1 May-2006
DOI: 10.3833/pdr.v2006.i71.517 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
In a pivotal reversal of roles, Pharmacopeia Drug Discovery (PDD) has exclusively licensed from global giant Bristol-Myers Squibb (BMS) preclinical compounds arising from a BMS discovery programme...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS